



Adverse Neonatal Outcomes Associated with COVID-19: A Case-Control Study in Pregnant Women

Firoozeh Rakhshani Moghaddam¹, Maryam Razavi ^{1,2,*}, Marzieh Mohammadi Ayoubi³

¹ Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

² Health Promotion Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

³ School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

*Corresponding Author: Department of Obstetrics and Gynecology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran. Email: dr.razavi351@gmail.com

Received: 5 October, 2024; Revised: 25 March, 2025; Accepted: 27 April, 2025

Abstract

Background: The COVID-19 pandemic has posed significant challenges to healthcare systems worldwide, particularly affecting vulnerable populations such as pregnant women. This study aims to investigate the impact of COVID-19 on maternal and neonatal outcomes among pregnant women admitted to Ali-Ibn-Abi-Taleb Hospital in Zahedan, Iran, from September 2020 to September 2021.

Objectives: To assess the impact of COVID-19 on gestational age at delivery, Apgar scores, neonatal intensive care unit (NICU) admissions, low birth weight (LBW), and neonatal respiratory symptoms among pregnant women.

Methods: A total of 180 pregnant women were included in this case-control study, with 90 COVID-19-positive cases and 90 matched controls. Key outcomes assessed included gestational age at delivery, Apgar scores, NICU admissions, LBW, and neonatal respiratory symptoms.

Results: The study found that COVID-19 significantly increased the risk of preterm birth (< 37 weeks) ($P = 0.048$), lower Apgar scores at 1 and 5 minutes ($P < 0.001$), NICU admissions ($P < 0.001$), and LBW ($P < 0.001$). Additionally, neonatal respiratory symptoms were more frequent in the COVID-19 group ($P = 0.007$). While there was a higher incidence of neonatal mortality in the COVID-19 group, the difference was not statistically significant ($P = 0.051$). The timing of maternal COVID-19 infection also played a critical role, with second-trimester infections being significantly associated with congenital anomalies ($P = 0.002$).

Conclusions: This study reveals the increased risks associated with COVID-19 during pregnancy and underscores the need for targeted strategies to mitigate these risks in affected populations. Further research is essential to understand the mechanisms driving these outcomes and to inform clinical practice and public health policies.

Keywords: COVID-19, Maternal and Neonatal Outcomes, Preterm Birth, Neonatal Intensive Care Unit

1. Background

Coronaviruses (CoVs) are ribonucleic acid (RNA) viruses that infect a wide range of host species, including domestic and farm animals as well as bats. They were first identified in the 1960s (1). This viral family can cause a variety of diseases, ranging from the common cold to severe acute respiratory syndrome (SARS) in humans (2). Common symptoms include fever, cough, chest pain, particularly tightness, and dyspnea or shortness of breath. Many cases experience a mild course of the disease (3). Studies have shown that

pregnant women with SARS have worse outcomes compared to non-pregnant women of the same age (4). Spontaneous abortion has been reported in cases infected with SARS during the first trimester. Additionally, intrauterine growth restriction (IUGR) and preterm birth have been observed in pregnancies affected by SARS in the second and third trimesters. Neonatal intensive care unit (NICU) admission, endotracheal intubation, renal failure, and maternal mortality have also been noted in this population (5). However, no cases of vertical transmission of SARS-CoV from mother to fetus have been confirmed (6).

Copyright © 2025, Rakhshani Moghaddam et al. This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (<https://creativecommons.org/licenses/by/4.0/>), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

How to Cite: Rakhshani Moghaddam F, Razavi M, Mohammadi Ayoubi M. Adverse Neonatal Outcomes Associated with COVID-19: A Case-Control Study in Pregnant Women. Arch Pediatr Infect Dis. 2025; In Press (In Press): e156824. <https://doi.org/10.5812/apid-156824>.

Study by Yu et al. (7) and Schmid et al. (8) found no perinatal SARS infections in neonates born to mothers infected during pregnancy. Khan et al. suggested that COVID-19 might result in long-term congenital disorders in neonates through infections, which is particularly concerning in resource-constrained developing countries where prenatal screening is often lacking. The prevalence of COVID-19 in these countries remains high (9).

Pregnancy is typically managed by obstetricians and gynecologists, while COVID-19 is handled by virologists and infectious disease specialists. Therefore, intersectoral collaboration and information exchange are crucial to prevent complications in neonates (9). Notably, some pregnancies have had good outcomes despite maternal SARS infection (10). Given that 68 - 85% of SARS-CoV-2 cases share sequence similarity with SARS, COVID-19 may follow a similar trend in pregnant women. Although SARS-CoV-2 shares similarities with other CoVs, it appears to be more contagious across different populations (6). Consequently, pregnant women and neonates should be prioritized in COVID-19 prevention and management strategies (11).

In a previous study, we evaluated maternal and neonatal outcomes in pregnancies positive for SARS-CoV-2 over a 6-month period (2019 - 2020). This retrospective study included 100 SARS-CoV-2-positive pregnant women and 50 healthy controls from hospitals affiliated with Zahedan University of Medical Sciences across five cities in Sistan and Baluchestan. The results indicated an increased risk of preterm birth and associated complications, as well as varied maternal and neonatal outcomes among SARS-CoV-2-positive pregnancies (12).

2. Objectives

Building on these findings, the current study was designed to evaluate additional characteristics and parameters with a more comprehensive approach. Conducted over a one-year period (September 2020 to September 2021) in Zahedan, this study aimed to provide a deeper understanding of the impact of COVID-19 on maternal and neonatal health in our province by analyzing a broader set of data and outcomes. Therefore, the present study aimed to evaluate the impact of COVID-19 on maternal and neonatal outcomes by comparing a group of COVID-19-positive pregnant mothers with a control group of healthy pregnant mothers in Zahedan, Sistan and Baluchestan province, Iran.

3. Methods

This retrospective study employed a case-control research design. The statistical population consisted of case and control groups, including the medical records of all pregnant women admitted to the maternity ward of Ali-Ibn-Abi-Taleb Hospital, Zahedan, Iran, from September 2020 to September 2021. The study commenced upon receiving approval from the Research Council of the School of Medicine at Zahedan University of Medical Sciences, Zahedan, Iran (IR.ZAUMS.REC.1401.013).

The inclusion criteria for the case group comprised the medical records of all pregnant women admitted to the maternity ward with a documented history of COVID-19 infection during pregnancy, confirmed through a positive RT-PCR test, provided that these records were complete. Exclusion criteria included a history of preeclampsia, gestational diabetes mellitus (GDM), stillbirth, fetal anomalies, incomplete medical records, and the inability to contact the pregnant women when records were deficient.

Once included in the study, relevant data such as maternal age, neonatal gender, parity, type of delivery, 1- and 5-minute Apgar scores, gestational age, timing of maternal COVID-19 infection, neonatal mortality up to 30 days, neonatal admission to the NICU, and low birth weight (LBW) were extracted from the medical records and entered into the information form. Missing data were carefully addressed. For any missing data from the medical records, efforts were made to contact the mothers directly to obtain the required information. If this was not possible, the data were considered missing and excluded from the respective analysis. The sample selection process, including inclusion and exclusion criteria, is illustrated in Figure 1.

The study sample comprised all available and eligible cases within the study period, totaling 180 pregnant women, divided into case ($n = 90$) and control ($n = 90$) groups. The case group included all pregnant women with confirmed COVID-19 infection during the study period who met the inclusion criteria. The control group was selected by matching non-infected pregnant women based on maternal age, type of delivery, and parity to ensure comparability. As this was a retrospective study, the sample size was not determined by an a priori power calculation but rather reflected the total number of eligible cases within the one-year study period.

3.1. Statistical Analysis

For data analysis, the normality of continuous variables (e.g., maternal age, Apgar scores) was assessed using the one-sample Kolmogorov-Smirnov (K-S) test. If




Figure 1. Flow diagram illustrating participant selection and inclusion/exclusion criteria in the study

normality was confirmed, the independent samples *t*-test was applied for comparisons between groups. For categorical variables (e.g., NICU admission, LBW, congenital anomalies), the chi-square test was used. If expected frequencies in any cell were < 5 , Fisher's exact test was performed instead. All tests were conducted using IBM SPSS Statistics (version 26) software, with a significance level set at less than 0.05.

4. Results

In this study, 180 pregnant women were divided into case ($n = 90$) and control ($n = 90$) groups, respectively infected and not infected with COVID-19, to determine the frequency of complications in neonates born to mothers infected with COVID-19.

4.1. Maternal Demographics

According to Table 1, the demographic characteristics of the mothers in both the COVID-19 group and the control group were largely similar, with no significant differences in age or gravida. The mean \pm standard deviation (SD) age of the pregnant women with COVID-19 was 31.46 ± 5.56 years, and that of the controls was 30.76 ± 5.84 years ($P = 0.309$).

4.2. Neonatal Outcomes

As shown in Table 2, neonatal outcomes were markedly worse in the COVID-19 group compared to the control group. The NICU admission was significantly more common among infants born to COVID-19-positive mothers (25.56% vs. 0%, $P < 0.001$). The incidence of LBW was also significantly higher in the COVID-19 group (28.89% vs. 6.67%, $P < 0.001$). Neonatal respiratory symptoms were more frequent in the COVID-19 group (69.23% vs. 30.77%, $P = 0.007$), and there was a higher rate of congenital anomalies, although this was not statistically significant (7.78% vs. 3.33%, $P = 0.193$). Additionally, there were notable differences in gestational age at delivery. The COVID-19 group had a higher rate of preterm births (< 37 weeks) at 32%, compared to 20% in the control group ($P = 0.048$). Apgar scores were significantly lower in the COVID-19 group, both at 1 minute (7.57 ± 2.53 vs. 8.87 ± 0.34 ; $P < 0.001$) and at 5 minutes (8.84 ± 2.13 vs. 9.87 ± 0.34 ; $P < 0.001$). Although mortality rates were higher in the COVID-19 group, this difference was not statistically significant ($P = 0.051$). Mortality rates in each group were calculated by dividing the number of neonatal deaths within 30 days of birth by the total number of neonates in the

Table 1. The Demographic Data and Complications of Mothers in the Study and Control Group ^a

Variables	Covid-19 Mothers (N = 90)	Control Group (N = 90)	P-Value
Age	31.46 ± 5.56	30.76 ± 5.84	0.309
Neonatal sex			0.289
Male	41 (45.56)	33 (36.67)	
Female	49 (54.44)	57 (63.33)	
Mode of delivery			0.221
Cesarean section	51 (56.67)	59 (65.56)	
Normal vaginal delivery	39 (43.33)	31 (34.44)	
Gravida	2.29 ± 2.00	2.67 ± 1.97	0.198
Trimester of pregnancy at infection			-
First trimester	22 (24.44)	-	
Second trimester	26 (28.89)	-	
Third trimester	42 (46.67)	-	

^a Values are expressed as No. (%) or mean ± SD.

Table 2. The Comparative Analysis of Neonatal Outcomes in Pregnant Mothers with COVID-19 (n = 90) and Healthy Mothers (n = 90) ^a

Clinical Characteristics	Infected Mothers	Healthy Mothers	P-Value ^b
NICU admission			< 0.001
Yes	23 (25.56)	0 (0)	
No	67 (74.44)	90 (100)	
LBW			< 0.001
Yes	26 (28.89)	6 (6.67)	
No	64 (71.11)	84 (93.33)	
Congenital anomaly			0.193
Yes	7 (7.78)	83 (92.22)	
No	3 (3.33)	87 (96.67)	
Neonatal respiratory symptoms			0.007
Yes	27 (69.23)	12 (30.77)	
No	63 (44.68)	78 (55.32)	
Gestational age (wk)			0.048
< 37 (term)	58 (64.44)	70 (77.78)	
> 37 (preterm)	32 (35.56)	20 (22.22)	
Apgar score			
1st min of life	7.57 ± 2.53	8.87 ± 0.34	< 0.001
5th min of life	8.84 ± 2.13	9.87 ± 0.34	< 0.001

^z Abbreviations: NICU, neonatal intensive care unit; LBW, low birth weight.

^a Values are expressed as No (%) or mean ± SD.

^b P-value ≤ 0.05 is considered statistically significant.

respective group (n = 90). For the case group, 8 neonates died, resulting in a mortality rate of 8.89%, and for the control group, 3 neonates died, resulting in a mortality rate of 3.33%.

4.3. Impact of COVID-19 Infection Timing

Our results showed that the timing of COVID-19 infection during pregnancy appeared to influence neonatal outcomes. As presented in [Table 3](#), infant mortality was highest among mothers infected during the third trimester (14.28%), although this finding was not statistically significant (P = 0.157). Congenital anomalies were most common when infection occurred in the second trimester (85.71%, P = 0.002). Neonatal

Table 3. Comparison of Infant Complication Rates Among Mothers with and Without COVID-19 ^a

Trimester of Maternal COVID-19 Infection	Yes	No	P-Value ^b
Infant mortality			0.157
1st	0 (0)	22 (100)	
2nd	2 (7.69)	24 (92.31)	
3rd	6 (14.28)	36 (85.72)	
Total	8 (8.89)	82 (91.11)	
Congenital anomaly			0.002
1st	0 (0)	22 (26.50)	
2nd	6 (85.71)	20 (24.09)	
3rd	1 (14.29)	41 (49.39)	
Total	7 (100)	83 (100)	
Neonatal respiratory symptoms			0.654
1st	7 (31.81)	15 (68.18)	
2nd	6 (23.07)	20 (76.92)	
3rd	14 (43.75)	28 (66.67)	
Total	27 (30)	63 (70)	

^a Values are expressed as No (%) or mean \pm SD.

^b P-value \leq 0.05 is considered statistically significant.

respiratory symptoms were more prevalent when mothers were infected in the third trimester, though the differences were not statistically significant ($P = 0.654$).

4.4. Congenital Malformations

An analysis of congenital malformations revealed a significant association with maternal age and neonatal sex (Table 4). Infants born to mothers aged 31 - 40 years had a higher incidence of congenital anomalies (70%) compared to other age groups ($P = 0.54$). Female infants were more likely to have congenital anomalies (90%) compared to males (10%), a difference that was statistically significant ($P = 0.04$). Moreover, no significant relationship was observed between maternal pregnancy diseases and congenital anomalies ($P = 0.425$).

5. Discussion

Considerable attention has been directed toward the impact of the COVID-19 pandemic on pregnant women, who face high risks due to their increased susceptibility to respiratory infections and severe pneumonia. The interaction of COVID-19 with pregnancy-specific immune and anatomical changes may elevate the risk of infection and subsequently influence both immune responses and maternal-neonatal health outcomes. Previous studies on other CoVs, such as SARS, have established their association with severe perinatal

complications, including miscarriage, IUGR, and congenital disorders (13).

Despite the global focus on COVID-19, there remains a significant gap in understanding its specific effects during pregnancy, particularly in underrepresented populations. This study aimed to address this gap, providing crucial insights into the complications associated with SARS-CoV-2 infection during pregnancy in Sistan and Baluchestan province, Iran. The findings of this study showed the effect of COVID-19 on maternal and neonatal outcomes, emphasizing challenges faced by pregnant women during the pandemic. The significant differences observed in gestational age at delivery, NICU admissions, and the prevalence of LBW among infants born to COVID-19-positive mothers reveal the extent to which the virus can complicate pregnancy.

Our findings revealed that COVID-19 during pregnancy significantly increased the risk of preterm birth, NICU admission, LBW, and lower Apgar scores, aligning with similar studies. We also observed more frequent neonatal respiratory symptoms in the COVID-19 group. Our study identified the timing of infection as a critical factor, particularly with congenital anomalies associated with second-trimester infections. These results not only emphasize the vulnerability of this population but also raise critical questions about the long-term implications for both mothers and their newborns. Understanding these outcomes is essential for informing clinical practices and public health

Table 4. Frequency of Congenital Malformations in Infants Born by Mothers with and Without COVID-19 Infection ^a

Maternal Age	Yes	No	P-Value ^b
Congenital anomaly			0.54
< 20	0 (0)	2 (1.17)	
21 - 30	3 (30)	74 (43.52)	
31 - 40	7 (70)	80 (47.05)	
41 - 50	0 (0)	11 (6.47)	
Neonatal sex			0.04
Boy	1 (10)	73 (42.94)	
Girl	9 (90)	97 (57.05)	
Maternal pregnancy diseases			
Present	4 (7.69)	48 (92.31)	0.425
Absent	6 (4.68)	122 (95.32)	

^a Values are expressed as No (%) or mean \pm SD.

^b P-value \leq 0.05 is considered statistically significant.

strategies to protect pregnant women in the face of ongoing and future pandemics.

Some studies have demonstrated that patients in the acute phase of COVID-19 may face cytokine release syndrome (CRS). Viral infections can cause dysfunction or failure of multiple organs. Pulmonary involvement with higher pro-inflammatory interleukins (ILs) and tumor necrosis factor alpha (TNF- α) are associated with mortality. On the other hand, pregnancy has been shown to aid the body's immune system in reaching modulation. Gonadotropin (GNT) and progesterone (PGT) inhibit the T1 pro-inflammatory pathway through TNF- α reduction, and it has been reasoned that the modulated immune system may protect pregnant women against CRS and its associated mortality. Therefore, pregnant women may be at fewer risks, although neonatal complications can be seriously detrimental (14).

Based on the study findings, the 1- and 5-minute Apgar scores of the neonates born to COVID-19-positive mothers were significantly lower in the case group than in the controls. Li et al. found in their case-control study on maternal-neonatal outcomes in pregnant women with COVID-19 that the 1-minute Apgar score was significantly lower in the case group than in the control group (15). In a prospective cohort study on congenital COVID-19 infection, Antoun et al. reported that 29% of the cases contracted the disease and established that the 1-, 3-, and 5-minute Apgar scores were significantly lower than those in the control group, consistent with the present study (16).

The frequency of gestational age below 37 weeks (preterm), NICU admission, LBW, and respiratory symptoms in pregnant women with COVID-19 were

higher than those in the controls. As a result, the mortality rate in neonates born to COVID-19-positive mothers was higher than in the control group, indicating a borderline significant difference. Vilar et al. investigated maternal-neonatal complications and mortality rates among pregnant women and a control group in a multinational cohort study. Their findings showed that COVID-19 increased the probability of preterm birth (59%), fetal distress (70%), NICU admissions (97%), and birth weight below 2500 g (58%) but decreased gestational age (39%) (17). Additionally, Li et al. verified that the frequency of LBW and preterm birth in neonates born to mothers infected with COVID-19 was significantly higher than in the control group (15).

Mullins et al. reported that the most common maternal outcomes associated with COVID-19 infection were fetal distress, premature rupture of membranes (PROM), and preterm delivery. Notably, 42% of mothers infected with the virus gave birth prematurely (18). Similarly, Gupta et al. found an association between COVID-19 infection and an increase in preterm births, suggesting that the use of antiviral drugs, which can stimulate labor, may contribute to this outcome (19). Additionally, Azh et al. reported that higher rates of preterm delivery are associated with increased rates of infant mortality (20). They found that infants born to mothers infected with COVID-19 had a significant incidence of poor neonatal outcomes, including respiratory distress, fever, tachycardia, gastrointestinal bleeding, nutritional intolerance, and milk regurgitation.

Alserehi et al. demonstrated that the most common neonatal complications were prematurity, low

gestational age, fetal distress, LBW, and bacterial pneumonia. Their study also revealed that 50% of these infants required NICU hospitalization, 23% needed mechanical ventilation, and 57% experienced spontaneous abortions. Most of the mothers in this study were infected during the first trimester, and 80% of the infants were born prematurely. These findings suggest that infants with underlying conditions and those born before 37 weeks are at higher risk of severe disease caused by COVID-19 (21).

The study findings did not reveal a significant difference in congenital disorders with respect to COVID-19 infection and non-infection. Nevertheless, these abnormalities were more common in the second trimester. This discrepancy highlights the importance of increased care during different time periods to avoid contracting COVID-19. During this period, the rapid development of fetal organs could trigger problems; therefore, it is crucial to prevent and manage COVID-19 infection to minimize complications.

In our previous study, we reported a 37% prevalence of preterm birth and a significant incidence of complications such as acute respiratory distress syndrome (21%) and stillbirth (10%) among pregnant women with COVID-19. The present study found a slightly lower preterm birth rate of 32%, though neonatal outcomes such as NICU admissions (25.56%), LBW (28.89%), and respiratory symptoms (69.23%) were notably higher. Furthermore, our earlier research documented a cesarean section rate of 30% among COVID-19-positive pregnancies, whereas the current study shows an increased rate of 56.67%, potentially reflecting changes in clinical management or differing population characteristics (12).

Both studies illustrate the considerable risks posed by COVID-19 during pregnancy, but the current study provides additional insights into the timing of infection, with second-trimester infections showing a significant association with congenital anomalies ($P = 0.002$), a factor not evaluated in the earlier work. Together, these findings confirm the expanding understanding of maternal and neonatal risks correlated with COVID-19.

Similarly, a case-control study in southern Iran reported higher rates of vaginal bleeding, fetal distress, preterm birth, intrauterine death, ICU admission, LBW, and NICU admission among COVID-19-infected pregnant women. While neonatal transient tachypnea, pneumonia, and abnormal lung X-rays were more common, these differences were not statistically significant (22). These findings align with our results, highlighting the need for enhanced prenatal

monitoring and pregnancy-specific interventions to improve maternal and neonatal outcomes.

5.1. Conclusions

The study demonstrates that COVID-19 during pregnancy is associated with increased risks of preterm birth, lower Apgar scores, NICU admissions, LBW, and neonatal respiratory symptoms. The timing of infection during pregnancy appears to play a crucial role in determining neonatal outcomes, particularly regarding congenital anomalies and infant mortality. Further research is needed to explore the mechanisms behind these associations and to develop strategies for mitigating these risks in pregnant women affected by COVID-19.

5.2. Limitations

There were some limitations in this study. First, there was no access to all medical records, which was addressed by obtaining permission from the Ethics Committee and providing it to the relevant officials. Second, inaccuracies in the review of medical records could affect the study results. To address this, a medical student informed of the conditions and knowledgeable about the study objectives supervised data collection alongside the researcher. Third, the incompleteness of medical records in terms of the information needed for the present study was also a limitation, so such cases were excluded.

Acknowledgements

The present study was derived from a medical doctor's dissertation at Zahedan University of Medical Sciences. The authors would like to thank the study participants and the personnel of Ali-Ibn-Abi-Taleb Hospital and the Maternity Ward for their cooperation and support throughout this study. Their assistance was valuable in facilitating data collection and ensuring the study's success.

Footnotes

Authors' Contribution: Study concept and design: M. R.; Analysis and interpretation of data: M. R. and M. M.; Drafting of the manuscript: F. R. and M. M.; Critical revision of the manuscript for important intellectual content: M. R.; Statistical analysis: M. R. and M. M.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author during submission or after publication.

Ethical Approval: IR.ZAUMS.REC.1401.013.

Funding/Support: The present study received no financial support for the research, authorship, and publication of this study.

Informed Consent: It was not declared by the authors.

References

- Lau SK, Lee P, Tsang AK, Yip CC, Tse H, Lee RA, et al. Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination. *J Virol*. 2011;**85**(21):11325-37. [PubMed ID: 21849456]. [PubMed Central ID: PMC3194943]. <https://doi.org/10.1128/JVI.05512-11>.
- Sohrabi C, Alsafi Z, O'Neill N, Khan M, Kerwan A, Al-Jabir A, et al. World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19). *Int J Surg*. 2020;**76**:71-6. [PubMed ID: 32112977]. [PubMed Central ID: PMC7105032]. <https://doi.org/10.1016/j.ijsu.2020.02.034>.
- Lake MA. What we know so far: COVID-19 current clinical knowledge and research. *Clin Med (Lond)*. 2020;**20**(2):124-7. [PubMed ID: 32139372]. [PubMed Central ID: PMC7081812]. <https://doi.org/10.7861/clinmed.2019-coron>.
- Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM*. 2020;**2**(2):100107. [PubMed ID: 32292902]. [PubMed Central ID: PMC7104131]. <https://doi.org/10.1016/j.ajogmf.2020.100107>.
- Qiao J. What are the risks of COVID-19 infection in pregnant women? *Lancet*. 2020;**395**(10226):760-2. [PubMed ID: 32151334]. [PubMed Central ID: PMC7158939]. [https://doi.org/10.1016/S0140-6736\(20\)30365-2](https://doi.org/10.1016/S0140-6736(20)30365-2).
- Rasmussen SA, Smulian JC, Lednický JA, Wen TS, Jamieson DJ. Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians need to know. *Am J Obstet Gynecol*. 2020;**222**(5):415-26. [PubMed ID: 32105680]. [PubMed Central ID: PMC7093856]. <https://doi.org/10.1016/j.ajog.2020.02.017>.
- Yu N, Li W, Kang Q, Xiong Z, Wang S, Lin X, et al. Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study. *Lancet Infect Dis*. 2020;**20**(5):559-64. [PubMed ID: 32220284]. [PubMed Central ID: PMC7158904]. [https://doi.org/10.1016/S1473-3099\(20\)30176-6](https://doi.org/10.1016/S1473-3099(20)30176-6).
- Schmid MB, Fontijn J, Ochsenbein-Kolble N, Berger C, Bassler D. COVID-19 in pregnant women. *Lancet Infect Dis*. 2020;**20**(6):653. [PubMed ID: 32197098]. [PubMed Central ID: PMC7270341]. [https://doi.org/10.1016/S1473-3099\(20\)30175-4](https://doi.org/10.1016/S1473-3099(20)30175-4).
- Khan MSI, Nabeka H, Akbar SMF, Al Mahtab M, Shimokawa T, Islam F, et al. Risk of congenital birth defects during COVID-19 pandemic: Draw attention to the physicians and policymakers. *J Glob Health*. 2020;**10**(2):20378. [PubMed ID: 33274057]. [PubMed Central ID: PMC7690649]. <https://doi.org/10.7189/jogh.10.020378>.
- Elwood C, Boucoiran I, VanSchalkwyk J, Money D, Yudin M, Poliquin V. WITHDRAWN: SOGC Committee Opinion – COVID-19 in Pregnancy. *J Obstet Gynaecol Can*. 2020. <https://doi.org/10.1016/j.jogc.2020.03.012>.
- Liu H, Wang LL, Zhao SJ, Kwak-Kim J, Mor G, Liao AH. Why are pregnant women susceptible to COVID-19? An immunological viewpoint. *J Reprod Immunol*. 2020;**139**:103122. [PubMed ID: 32244166]. [PubMed Central ID: PMC7156163]. <https://doi.org/10.1016/j.jri.2020.103122>.
- Ghalandarzahi A, Razavi M, Rakhshani Moghaddam F. Maternal and Neonatal Outcomes in Pregnancies Positive for SARS-CoV-2. *J Nurs Midwifery Sci*. 2024;**11**(2). e147465. <https://doi.org/10.5812/jnms-147465>.
- Wang W, Zhang Q, Qu F. The potential benefits of Chinese integrative medicine for pregnancy women during the COVID-19 pandemic. *Integr Med Res*. 2020;**9**(3):100461. [PubMed ID: 32704474]. [PubMed Central ID: PMC7311349]. <https://doi.org/10.1016/j.imr.2020.100461>.
- Cheon SY, Koo BN. Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2. *Int J Mol Sci*. 2021;**22**(15). [PubMed ID: 34360684]. [PubMed Central ID: PMC8348456]. <https://doi.org/10.3390/ijms22157914>.
- Li N, Han L, Peng M, Lv Y, Ouyang Y, Liu K, et al. Maternal and Neonatal Outcomes of Pregnant Women With Coronavirus Disease 2019 (COVID-19) Pneumonia: A Case-Control Study. *Clin Infect Dis*. 2020;**71**(16):2035-41. [PubMed ID: 32249918]. [PubMed Central ID: PMC7184430]. <https://doi.org/10.1093/cid/ciaa352>.
- Antoun L, Taweel NE, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study. *Eur J Obstet Gynecol Reprod Biol*. 2020;**252**:559-62. [PubMed ID: 32732059]. [PubMed Central ID: PMC7362841]. <https://doi.org/10.1016/j.ejogrb.2020.07.008>.
- Villar J, Ariff S, Gunier RB, Thiruvengadam R, Rauch S, Kholin A, et al. Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study. *JAMA Pediatr*. 2021;**175**(8):817-26. [PubMed ID: 33885740]. [PubMed Central ID: PMC8063132]. <https://doi.org/10.1001/jamapediatrics.2021.1050>.
- Mullins E, Evans D, Viner RM, O'Brien P, Morris E. Coronavirus in pregnancy and delivery: rapid review. *Ultrasound Obstet Gynecol*. 2020;**55**(5):586-92. [PubMed ID: 32180292]. <https://doi.org/10.1002/uog.22014>.
- Gupta A, Sarna R, Singla V, Chauhan R, Bloria S. COVID19 and pregnancy- Two lives at risk. *J Anesth Crit Care Open Access*. 2020;**12**(4):157-60. <https://doi.org/10.15406/jaccoa.2020.12.00452>.
- Azh N, Pakniat H, Rajabi M, Ranjesh F. [Evaluation of Pregnancy Outcomes in Pregnant Women with COVID-19 in Qazvin 1399]. *Iran J Epidemiol*. 2021;**16**(5):10-9. FA.
- Alserehi H, Wali G, Alshukairi A, Alraddadi B. Impact of Middle East Respiratory Syndrome coronavirus (MERS-CoV) on pregnancy and perinatal outcome. *BMC Infect Dis*. 2016;**16**:105. [PubMed ID: 26936356]. [PubMed Central ID: PMC4776369]. <https://doi.org/10.1186/s12879-016-1437-y>.
- Davoodi M, Barzegar H, Bahrami R, Najib KS. Evaluation of Neonatal and Maternal Outcomes in Pregnant Women with COVID-19 in Southern Iran: A Case-Control Study. *Arch Pediatr Infect Dis*. 2024;**13**(2). e150381. <https://doi.org/10.5812/apid-150381>.